Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mediwound (DE:M8W)
FRANKFURT:M8W
Mediwound (M8W) Stock Price & Analysis
0 Followers
M8W Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€6.45 - €18.70
Previous Close€15.6
Volume0.00
Average Volume (3M)482.00
Market Cap
€140.30M
Enterprise Value€107.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta0.74
Next Earnings
May 22, 2024EPS Estimate
-€0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,221,764
10 Day Avg. Volume183
30 Day Avg. Volume482
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.63
Price to Sales (P/S)7.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.38Price Target Upside56.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Mediwound News
PremiumCompany Announcements
MediWound Boasts Robust 2023 Financials and Growth
Bulls Say, Bears Say
Bulls Say
Expansion Of MarketPotential marketing approval for pediatric use of NexoBrid could notably widen its market, promising increased sales prospects.
Manufacturing Scale-UpMediWound's strategic investment in a new manufacturing facility is poised to substantially boost production capacity, readying the company for heightened product demand.
Revenue GrowthAnalyst expects robust revenue growth for NexoBrid, projecting a surge of over 40% in 2024 following its successful launch in significant markets.
Bears Say
Clinical TrialThe company has had to adjust its clinical trial strategy by reducing the number of participants, potentially impacting the robustness of trial outcomes.
EarningsTotal revenue in Q3 was significantly lower than the previous year, mainly as a result of missing one-time income that had boosted past figures.
Revenue DeclineA noticeable decrease in quarterly revenue has been observed, signaling potential challenges in the company's ability to generate consistent income streams.
---
M8W FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was €6.45 and its highest was €18.70 in the past 12 months.
What is Mediwound’s market cap?
Currently, no data Available
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is May 22, 2024 which is in 23 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Mar 21, 2024. The company reported -€0.178 earnings per share for the quarter, beating the consensus estimate of -€0.246 by €0.068.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -€0.38.
How many shares outstanding does Mediwound have?
Currently, no data Available
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -€0.178 in its last earnings report, beating expectations of -€0.246. Following the earnings report the stock price went up 5.634%.
Which hedge fund is a major shareholder of Mediwound?
Among the largest hedge funds holding Mediwound’s share is ARK Investment Management LLC. It holds Mediwound’s shares valued at N/A.
---
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.38 (56.25% Upside)
€24.38 (56.25% Upside)
Blogger Sentiment
Bullish
DE:M8W Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.97%
12-Months-Change
Fundamentals
Return on Equity
-31.60%
Trailing 12-Months
Asset Growth
32.88%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
---
M8W Stock 12 Months Forecast
Average Price Target
€24.38
▲(56.25% Upside)
Technical Analysis
Best Analysts Covering M8W
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+43.37%
reiterated a buy rating last month
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +43.37% per trade.
---